EGFR and cancer: [19] The PFS and OS of the patients treated with second line EGFR-TKI followed by previous chemotherapy would be short because chemotherapy may induce more genetic alterations in cancer lesion, decreased TKI sensitivity and decrease the patient’s performance status.